Artificial Intelligence (AI) in Medical Diagnostics

Global Artificial Intelligence (AI) in Medical Diagnostics Market to Reach US$4.4 Billion by 2030

The global market for Artificial Intelligence (AI) in Medical Diagnostics estimated at US$1.3 Billion in the year 2024, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 22.2% over the analysis period 2024-2030. Software, one of the segments analyzed in the report, is expected to record a 24.0% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Hardware segment is estimated at 17.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$366.3 Million While China is Forecast to Grow at 20.9% CAGR

The Artificial Intelligence (AI) in Medical Diagnostics market in the U.S. is estimated at US$366.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$663.5 Million by the year 2030 trailing a CAGR of 20.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 20.1% and 18.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR.

Global Artificial Intelligence (AI) in Medical Diagnostics Market – Key Trends & Drivers Summarized

The Rapid Rise of AI in Medical Diagnostics

Artificial Intelligence (AI) is revolutionizing the field of medical diagnostics by significantly improving the speed, accuracy, and accessibility of disease detection and interpretation. As healthcare systems around the world contend with increasing patient loads, shortages of skilled professionals, and the rising complexity of diagnostic imaging and data, AI has emerged as a powerful enabler of smarter, data-driven diagnostics. By leveraging machine learning (ML), deep learning, computer vision, and natural language processing (NLP), AI systems are now capable of interpreting medical images, lab data, pathology reports, and genetic profiles with unprecedented precision. This shift is not only enhancing clinical decision-making but also facilitating earlier and more targeted interventions across various conditions, including cancer, cardiovascular diseases, neurological disorders, and infectious diseases.

One of the most prominent trends in the market is the integration of AI into radiology and diagnostic imaging. AI algorithms are being trained on massive datasets to detect abnormalities in X-rays, CT scans, MRIs, and ultrasounds—flagging areas of concern for radiologists and reducing diagnostic errors. In parallel, AI-powered pathology platforms are transforming how tissue samples are analyzed by identifying patterns in histopathological images that may be invisible to the human eye. Another key trend is the use of AI in point-of-care diagnostics and wearable health technologies, where real-time data collection is paired with AI to monitor vital signs, detect arrhythmias, or flag early signs of disease, allowing for timely intervention and improved patient outcomes.

How Is AI Enhancing Accuracy and Efficiency in Disease Detection?

AI systems are dramatically enhancing diagnostic accuracy, especially in areas where early detection is critical. In oncology, for instance, AI is being used to detect early-stage breast, lung, prostate, and skin cancers from imaging scans with accuracy comparable to or exceeding that of experienced clinicians. Deep learning algorithms can recognize subtle patterns, calculate tumor growth rates, and differentiate between benign and malignant lesions. In cardiology, AI-based ECG and imaging analysis tools assist in identifying arrhythmias, structural abnormalities, and even predicting heart failure risks based on longitudinal patient data.

In terms of efficiency, AI reduces the diagnostic workload by automating repetitive tasks and triaging cases based on urgency. This is particularly valuable in overburdened health systems where radiologists and lab technicians face increasing volumes of diagnostic tests. AI systems can prioritize scans with suspected anomalies, provide preliminary assessments, and reduce turnaround time significantly. In pathology, AI tools are enabling digital workflows where biopsy slides are scanned and analyzed at scale, accelerating diagnosis and enabling remote consultations. By streamlining diagnostics, AI helps clinicians make faster, more informed decisions, ultimately improving patient care and resource utilization.

Where Is AI Expanding Its Impact Across Diagnostic Specialties?

Beyond imaging and pathology, AI is being integrated into a wide range of diagnostic specialties. In genomics, AI platforms are helping interpret complex DNA and RNA sequencing data to identify genetic mutations, predict disease susceptibility, and guide precision medicine strategies. In infectious disease diagnostics, AI is being used to analyze clinical symptoms, lab data, and even microbial genomics to detect outbreaks, track resistance patterns, and optimize treatment protocols. During the COVID-19 pandemic, AI played a key role in the rapid analysis of viral spread, diagnostic imaging interpretation, and triage automation.

In neurology, AI systems are supporting early diagnosis of conditions like Alzheimer’s, Parkinson’s, and multiple sclerosis by analyzing imaging, speech patterns, and cognitive test results. In ophthalmology, AI is enabling early detection of diabetic retinopathy, glaucoma, and macular degeneration through retinal imaging analysis. AI-driven diagnostic tools are also being deployed in dermatology to differentiate between various skin lesions using mobile apps and dermatoscopic imaging. As electronic health records (EHRs) become more interoperable and rich in unstructured data, NLP-powered AI systems are helping extract insights from physician notes, lab reports, and patient histories to support comprehensive diagnostics.

What’s Fueling the Growth in the AI in Medical Diagnostics Market?

The growth in the AI in medical diagnostics market is driven by several factors closely linked to technological advancements, clinical needs, and global healthcare transformations. One of the primary growth drivers is the increasing volume of medical imaging and diagnostic data, which is overwhelming human capacity for interpretation. AI provides a scalable solution by rapidly processing large datasets and highlighting critical findings with high accuracy. Additionally, the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and diabetes is creating an urgent need for faster, more reliable diagnostic tools.

The advancement of deep learning, image recognition, and natural language processing algorithms, combined with the availability of large annotated datasets and cloud computing infrastructure, is enabling the development and deployment of sophisticated AI diagnostic tools. Regulatory bodies are increasingly approving AI-based diagnostic devices for clinical use, signaling a growing trust in AI’s clinical efficacy and safety. Furthermore, the expansion of telehealth and remote diagnostics—especially post-pandemic—is pushing healthcare providers to adopt AI-powered tools that support virtual consultations and at-home diagnostics.

AI’s potential to reduce healthcare costs by minimizing misdiagnoses, avoiding unnecessary procedures, and improving early detection is also driving adoption among payers and providers. Additionally, partnerships between healthcare institutions, AI startups, and tech giants are accelerating innovation and bringing cutting-edge diagnostic solutions to market. The rising interest in personalized and preventative medicine is further aligning with AI’s capabilities in risk prediction and patient stratification. Together, these drivers are not only fueling market growth but are also positioning AI as a central pillar in the future of diagnostic medicine—where precision, speed, and intelligence converge to deliver better health outcomes.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence (AI) in Medical Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Component (Software, Hardware, Services); Diagnosis Type (Neurology, Radiology, Oncology, Pulmonology, Cardiology, Other Diagnosis Types); End-User (Hospitals, Diagnostic Centers, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 22 Featured) -

• Agfa Healthcare Corporation
• Aidoc
• AliveCor, Inc.
• Caption Health
• Elevance Health, Inc.
• HeartFlow
• Intelegain Technologies
• Siemens Healthineers AG
• VisualDx.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs CBob geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.